Mereo BioPharma Group plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MREO research report →
Range $0.5 – $8
Price Chart
About the company
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment.
- CEO
- Denise Vera Scots-Knight
- IPO
- 2019
- Employees
- 39
- HQ
- London, GL, GB
Get TickerSpark's AI analysis on MREO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $55.88M
- P/E
- -1.92
- PEG
- -0.03
- P/S
- 0.00
- P/B
- 1.96
- EV/EBITDA
- -0.81
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -74.76%
- ROIC
- -111.41%
Latest fiscal year · YoY change
- Revenue
- $500.00K+0.0%
- Gross Profit
- $367.00K+0.0%
- Op Income
- $-38,257,000
- Net Income
- $-41,878,000+0.0%
- EPS
- $-0.26+0.0%
- OCF Growth
- +5.7%
- FCF Growth
- +7.6%
- 52W High
- $2.37
- 52W Low
- $0.20
- 50D MA
- $0.30
- 200D MA
- $0.41
- Beta
- 0.30
- RSI (14)
- 55
- Avg Volume
- 4.08M
No earnings-call transcripts are available for MREO yet.
- Free Float
- 100.0%
- Shares Outstanding
- 159.62M
- Float Shares
- 159.62M
of shares held by institutions
67 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rubric Capital Management LP | 15.31M | 0 |
| 683 Capital Management, LLC | 11.78M | ▼ 222.14K |
| Bank Of America Corp | 8.20M | ▼ 6 |
| Defilade Capital Management, L.P. | 7.56M | 0 |
| Newtyn Management, LLC | 3.00M | ▼ 4.08M |
| Tejara Capital Ltd | 2.04M | 0 |
| Ubs Group AG | 1.45M | ▼ 42.50K |
| Two Sigma Investments, LP | 1.32M | ▲ 1.13M |
| Ecor1 Capital, LLC | 1.00M | ▼ 12.37M |
| Jane Street Group, LLC | 774.94K | ▲ 634.97K |
| Ishara Investments LP | 768.75K | ▲ 768.75K |
| Wealthspire Advisors, LLC | 765.00K | ▼ 31.04K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 26, 26 | Jacquet Pierre | other | 106,848 |
| Feb 26, 26 | Jacquet Pierre | other | 66,000 |
| Feb 26, 26 | Yoskowitz Marc J | other | 96,163 |
| Feb 26, 26 | Yoskowitz Marc J | other | 66,000 |
| Feb 26, 26 | Shames Daniel | other | 96,163 |
| Feb 26, 26 | Shames Daniel | other | 66,000 |
| Feb 26, 26 | Ekblom Anders | other | 133,560 |
| Feb 26, 26 | Ekblom Anders | other | 66,000 |
| Feb 26, 26 | Bender Jeremy | other | 117,533 |
| Feb 26, 26 | Bender Jeremy | other | 66,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MREO coverage
Recent articles, reports, and earnings notes.
No research on MREO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MREO report →Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
globenewswire.com · Aug 11
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
prnewswire.com · Aug 11
4basebio Announces Appointment of Chief Financial Officer and Board Changes
globenewswire.com · May 14
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com · May 12
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com · May 12
Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join – Contact Levi & Korsinsky
globenewswire.com · Apr 6
MREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO
globenewswire.com · Apr 6
MREO DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREO
newsfilecorp.com · Apr 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.